Meloxicam
Nonsteroidal anti-inflammatory drug (NSAID) / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Meloxicam?
Summarize this article for a 10 year old
Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis.[7][8] It is used by mouth or by injection into a vein.[8][9] It is recommended that it be used for as short a period as possible and at a low dose.[8]
Clinical data | |
---|---|
Trade names | Mobic, Metacam, Anjeso, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601242 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 89%[6] |
Protein binding | 99.4%[6] |
Metabolism | Liver (CYP2C9 and 3A4-mediated)[6] |
Elimination half-life | 20 hours[6] |
Excretion | Urine and feces equally[6] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.113.257 |
Chemical and physical data | |
Formula | C14H13N3O4S2 |
Molar mass | 351.40 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Common side effects include abdominal pain, dizziness, swelling, headache, and a rash.[8] Serious side effects may include heart disease, stroke, kidney problems, and stomach ulcers.[8] Use is not recommended in the third trimester of pregnancy.[8] It blocks cyclooxygenase-2 (COX-2) more than it blocks cyclooxygenase-1 (COX-1).[8] It is in the oxicam family of chemicals and is closely related to piroxicam.[8]
Meloxicam was patented in 1977 and approved for medical use in the United States in 2000.[8][10] It was developed by Boehringer Ingelheim; however, it is also available as a generic medication.[8] In 2021, it was the 32nd most commonly prescribed medication in the United States, with more than 18 million prescriptions.[11][12] An intravenous version of meloxicam (Anjeso) was approved for medical use in the United States in February 2020.[13][9]